Thus, we conducted a prospective study to evaluate the efficacy of both tissue NGS (tissue rebiopsy) and liquid NGS (liquid rebiopsy) at the time of cancer progression after first‐line EGFR‐TKI treatment in patients with advanced NSCLC. This evidence concerns the gene EGFR and cancer.